News

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field.

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

A PDUFA decision date of April 2, 2025 has been assigned

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

Optical coherence tomography will be in all eye care services by October 2025

Optical coherence tomography will be in all eye care services by October 2025

The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.

Retreatment rates are lower, with few orbit decompression procedures.

In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).

Assessing two devices in a real-world setting

This Week in Ophthalmology is a weekly video series highlighting the latest news and articles featured on the Ophthalmology Times website.

A coalition of eye health advocacy groups vocalized support for the legislation

A case report demonstrates independent effect of GLP-1 receptor agonist.

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s high rate of avoidable blindness. Trainees gain proficiency through simulation-based learning and live surgeries, improving access to eye care in remote areas.

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with Ophthalmology Times, Randall Olson, MD, lead author and a Distinguished Professor at the University of Utah, Chair of the Department of Ophthalmology and Visual Sciences, and CEO of the John A. Moran Eye Center, discusses the ongoing research.